Display options
Share it on

Neuropharmacology. 2022 Jan 01;202:108846. doi: 10.1016/j.neuropharm.2021.108846. Epub 2021 Oct 20.

CPP impairs contextual learning at concentrations below those that block pyramidal neuron NMDARs and LTP in the CA1 region of the hippocampus.

Neuropharmacology

Kurt Laha, Mengwen Zhu, Erin Gemperline, Vinuta Rau, Lingjun Li, Michael S Fanselow, Richard Lennertz, Robert A Pearce

Affiliations

  1. Department of Anesthesiology, University of Wisconsin-Madison, Madison, WI, USA. Electronic address: [email protected].
  2. Department of Anesthesiology, University of Wisconsin-Madison, Madison, WI, USA. Electronic address: [email protected].
  3. Department of Chemistry, University of Wisconsin-Madison, Madison, WI, USA. Electronic address: [email protected].
  4. Department of Anesthesiology, University of California-San Francisco, San Francisco, CA, USA. Electronic address: [email protected].
  5. Department of Chemistry, University of Wisconsin-Madison, Madison, WI, USA; School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA. Electronic address: [email protected].
  6. Departments of Psychology and Psychiatry, University of California, Los Angeles, Los Angeles, CA, USA. Electronic address: [email protected].
  7. Department of Anesthesiology, University of Wisconsin-Madison, Madison, WI, USA. Electronic address: [email protected].
  8. Department of Anesthesiology, University of Wisconsin-Madison, Madison, WI, USA. Electronic address: [email protected].

PMID: 34687710 PMCID: PMC8627488 DOI: 10.1016/j.neuropharm.2021.108846

Abstract

Drugs that block N-methyl-d-aspartate receptors (NMDARs) suppress hippocampus-dependent memory formation; they also block long-term potentiation (LTP), a cellular model of learning and memory. However, the fractional block that is required to achieve these effects is unknown. Here, we measured the dose-dependent suppression of contextual memory in vivo by systemic administration of the competitive antagonist (R,S)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP); in parallel, we measured the concentration-dependent block by CPP of NMDAR-mediated synapses and LTP of excitatory synapses in hippocampal brain slices in vitro. We found that the dose of CPP that suppresses contextual memory in vivo (EC50 = 2.3 mg/kg) corresponds to a free concentration of 53 nM. Surprisingly, applying this concentration of CPP to hippocampal brain slices had no effect on the NMDAR component of evoked field excitatory postsynaptic potentials (fEPSP

Copyright © 2021 Elsevier Ltd. All rights reserved.

Keywords: (R,S)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid; CPP; Contextual fear conditioning; LTP; Long term potentiation; NMDA receptors

References

  1. Anesthesiology. 1995 Jul;83(1):109-19 - PubMed
  2. Prog Brain Res. 2008;169:241-50 - PubMed
  3. Science. 1998 Jun 26;280(5372):2121-6 - PubMed
  4. Nat Commun. 2020 Mar 13;11(1):1382 - PubMed
  5. J Physiol. 1983 Jan;334:33-46 - PubMed
  6. Nat Neurosci. 2013 Aug;16(8):1032-41 - PubMed
  7. Biomolecules. 2020 Jun 23;10(6): - PubMed
  8. J Neurosci. 2013 May 22;33(21):9150-60 - PubMed
  9. J Neurosci Methods. 1995 Jun;59(1):5-9 - PubMed
  10. Methods Mol Biol. 2014;1183:221-42 - PubMed
  11. Amino Acids. 1998;14(1-3):207-16 - PubMed
  12. Mol Pharmacol. 2005 May;67(5):1591-9 - PubMed
  13. J Neurosci. 2018 Mar 14;38(11):2698-2712 - PubMed
  14. Cell. 1996 Dec 27;87(7):1339-49 - PubMed
  15. J Physiol. 2004 Jul 15;558(Pt 2):451-63 - PubMed
  16. Eur Neuropsychopharmacol. 2013 Nov;23(11):1623-35 - PubMed
  17. Nat Neurosci. 2012 Jul 15;15(8):1153-9 - PubMed
  18. Neuroscience. 2018 Mar 1;373:145-158 - PubMed
  19. J Alzheimers Dis. 2019;72(s1):S145-S176 - PubMed
  20. Nat Commun. 2020 Jul 13;11(1):3492 - PubMed
  21. Neuron. 2017 Jan 18;93(2):281-290 - PubMed
  22. Learn Mem. 2005 Jul-Aug;12(4):375-82 - PubMed
  23. J Physiol. 1983 Jan;334:19-31 - PubMed
  24. Brain Res. 1988 Oct 11;462(1):40-6 - PubMed
  25. Proc Natl Acad Sci U S A. 2010 Dec 28;107(52):22693-8 - PubMed
  26. Brain Res. 1986 Sep 10;382(1):169-73 - PubMed
  27. Behav Neurosci. 1992 Apr;106(2):274-85 - PubMed
  28. Methods Mol Biol. 2017;1677:1-80 - PubMed
  29. Bioorg Med Chem Lett. 2002 Apr 8;12(7):1099-102 - PubMed
  30. Neuroscience. 2010 Feb 17;165(4):1170-81 - PubMed
  31. Brain Res. 1986 Sep 10;382(1):174-7 - PubMed
  32. Curr Opin Pharmacol. 2021 Feb;56:93-101 - PubMed
  33. J Physiol. 1991 Jan;432:483-508 - PubMed
  34. J Pharmacol Exp Ther. 2006 Jul;318(1):434-43 - PubMed
  35. J Neurophysiol. 2016 Jun 1;115(6):3264-74 - PubMed
  36. J Neurosci. 2004 Aug 4;24(31):7015-23 - PubMed
  37. Curr Biol. 2017 Jun 19;27(12):1735-1745.e3 - PubMed
  38. EMBO J. 2014 Apr 16;33(8):842-61 - PubMed
  39. Nat Med. 1998 Apr;4(4):460-3 - PubMed
  40. Br J Anaesth. 2018 May;120(5):1019-1032 - PubMed
  41. Eur J Neurosci. 2005 Sep;22(5):1201-13 - PubMed
  42. Science. 1992 May 1;256(5057):675-7 - PubMed
  43. Sci Rep. 2014 Feb 05;4:3976 - PubMed
  44. Mol Brain. 2013 Jan 22;6:5 - PubMed
  45. J Biol Chem. 2011 Mar 4;286(9):7558-66 - PubMed
  46. Philos Trans R Soc Lond B Biol Sci. 2013 Dec 02;369(1633):20130129 - PubMed
  47. Anesth Analg. 2006 May;102(5):1397-406 - PubMed
  48. J Neurosci. 2006 Feb 1;26(5):1331-3 - PubMed
  49. Neuron. 2007 Sep 6;55(5):779-85 - PubMed
  50. Science. 2007 Jul 6;317(5834):94-9 - PubMed
  51. Proc Natl Acad Sci U S A. 2010 Sep 21;107(38):16697-702 - PubMed
  52. Neuron. 2018 Oct 10;100(1):106-119.e7 - PubMed
  53. Psychopharmacology (Berl). 1993;111(4):465-71 - PubMed
  54. Pharmacol Rev. 2010 Sep;62(3):405-96 - PubMed
  55. Physiol Rev. 2017 Oct 1;97(4):1619-1747 - PubMed
  56. Nat Commun. 2017 Jul 28;8(1):152 - PubMed
  57. Acta Anaesthesiol Scand. 2014 Oct;58(9):1127-33 - PubMed
  58. Br J Anaesth. 1988 May;60(6):680-91 - PubMed
  59. Cell. 1996 Dec 27;87(7):1327-38 - PubMed
  60. Behav Neurosci. 2009 Jun;123(3):624-30 - PubMed
  61. Front Behav Neurosci. 2015 Nov 09;9:298 - PubMed
  62. Science. 2008 Jul 4;321(5885):53-7 - PubMed
  63. J Neurosci. 2007 Dec 5;27(49):13457-67 - PubMed
  64. Br J Pharmacol. 1993 May;109(1):213-21 - PubMed
  65. Anesth Analg. 2003 Oct;97(4):1108-1116 - PubMed
  66. Neuroscience. 2015 Jul 9;298:26-41 - PubMed
  67. Pharmacol Ther. 2004 May;102(2):155-74 - PubMed
  68. Anesthesiology. 2007 Jan;106(1):114-23 - PubMed
  69. Anal Methods. 2014 Aug 21;6(16):6389-6396 - PubMed
  70. Br J Pharmacol. 1998 Aug;124(8):1607-14 - PubMed
  71. J Neurosci. 2015 Jul 1;35(26):9707-16 - PubMed
  72. Neuropharmacology. 2005 Mar;48(3):354-9 - PubMed
  73. J Neurosci. 2002 Jul 1;22(13):5462-72 - PubMed
  74. Nature. 1989 Mar 30;338(6214):425-7 - PubMed
  75. J Pharmacol Exp Ther. 1987 Mar;240(3):737-46 - PubMed
  76. J Pharmacol Exp Ther. 2020 Apr;373(1):103-112 - PubMed
  77. Hippocampus. 2004;14(1):66-76 - PubMed
  78. Nature. 1986 Feb 27-Mar 5;319(6056):774-6 - PubMed
  79. Eur J Pharmacol. 2014 Jan 15;723:29-37 - PubMed
  80. Anesthesiology. 2000 Apr;92(4):1055-66 - PubMed
  81. Biomolecules. 2020 Mar 18;10(3): - PubMed

Publication Types

Grant support